Contents
Contents
The Advanced Bionics false testing settlement required the cochlear implant manufacturer to pay $11.36 million to the United States and $1,238,580 to state Medicaid programs over allegations that it manipulated radio-frequency emissions tests and misled federal healthcare programs. A former engineer’s complaint explains what that meant inside the laboratory, where the settings that produced a passing report allegedly bore little resemblance to the settings needed to provide therapy.
The Justice Department announced the settlement on December 20, 2022. The company, based in Valencia, California, manufactures cochlear implant systems. The allegations concerned its Neptune and Naida sound processors and the emissions results it submitted in applications for FDA premarket approval. Patients needed functioning processors, while taxpayers funded processors whose test results allegedly came from settings that could not deliver therapy.
The former Advanced Bionics engineer brought the False Claims Act case. According to his first amended complaint, his first assignment was technical lead for the Neptune sound processor. His account reaches behind the passing score to show how the company allegedly obtained it.
The emissions tests measured radio-frequency energy that could interfere with other equipment, including phones, alarms, televisions and radios. The government alleged that Advanced Bionics claimed to meet an internationally recognized emissions standard while departing from its testing requirements.
The processor is the external part of the cochlear implant system. As the engineer’s complaint explains, it sends a radio-frequency signal to the implanted unit. That signal carries sound information and supplies power for the implanted stimulator. Turning down the radio-frequency output therefore changes something the system needs to function.
The complaint identifies the testing standard as CISPR-11 and alleges that Advanced Bionics submitted fraudulently obtained results to the FDA to secure approval. It explains that radio-frequency testing forms part of the safety and effectiveness review. The government’s allegation was concrete: Advanced Bionics failed to test in the required worst-case configurations and improperly shielded components that generated emissions. The approval submission relied on a passing test that allegedly did not represent how the processor operated.
The complaint alleged that Advanced Bionics combined a specially selected processor with shielding, a short cable and altered operating settings to obtain a passing result. Each choice allegedly changed what reached the laboratory’s measuring equipment.
The engineer described screening a batch of prototype units and finding a single Neptune processor with unusually low emissions. That unit became the one taken to laboratories for official testing. The complaint also described a shielded Test Box that held a reference implant and headpiece. It allegedly blocked emissions from components needed to operate the processor, even though the box was absent from production models.
Cable length mattered too. The complaint said the engineer was instructed to test with a nine-inch cable even though normal use could involve a cable up to 42 inches long. It alleged that units tested under real-world conditions consistently failed, particularly with longer cables.
The complaint put the combination in one sentence:
To summarize, this passing score was obtained only by (a) hand-selecting the unit with the lowest (in fact, abnormally low) emission; (b) using the shielded Test Box; (c) using the shortest possible coax cable; and (d) using “doctored” specifications described above.
Whistleblower’s allegation, United States, et al., ex rel. Nyberg v. Advanced Bionics Corp., first amended complaint, paragraph 102
The alleged selection process matters as much as the final score. An engineer who saw the batch being screened could explain why the processor that went to the test lab was unrepresentative of the other units.
For the Naida development project, the complaint described another way to lower emissions when a foreign laboratory would not allow the shielding boxes. A tool called Fake Lock allegedly let the sound processor behave as though it was connected to an implant without requiring the connection needed for normal operation.
That allowed the company to turn the radio-frequency power below the level needed to provide therapy, the engineer alleged. The complaint said the output could fall so low that the implant would not even have enough power to turn on.
The complaint alleged that low settings barely made the system work and did not resemble real-world therapy settings. It dated the practice of reducing test power as far as possible from January 2011 through August 2017 for both Neptune and Naida processors.
The engineer alleged that he told executive management about his concerns after returning from the test laboratory, and management accepted the passing report. His complaint described the response:
After his return from the TUV test lab, Relator communicated his concern with the results to AB executive management, but was told that a passing report was “good enough.”
Whistleblower’s allegation, United States, et al., ex rel. Nyberg v. Advanced Bionics Corp., first amended complaint, paragraph 105
According to the complaint, Advanced Bionics then submitted the result to the FDA. When China and South Korea requested testing samples, the company’s regulatory executive questioned whether the passing conditions could be reproduced overseas. The engineer alleged that his supervisor and executive management directed him to replicate the Test Boxes to conceal the emissions problems from those testing organizations.
The complaint also described a later systems director who wanted to understand the emissions problem. That director allegedly requested nighttime laboratory testing for his own review, followed by a report delivered only on a thumb drive. The engineer said the director prohibited email correspondence about the project.
Those allegations put decisions around the technical measurements: who requested the testing, who heard the concerns, what was submitted and what management asked employees to repeat.
In its national settlement announcement, the Justice Department alleged that Advanced Bionics submitted false emissions results in its approval applications and then itself sought reimbursement for the processors from Medicare, Medicaid and other federally funded health care programs. The announcement also describes the involvement of TRICARE, the Department of Veterans Affairs and the office overseeing health benefits for federal employees.
The 2020 Journal of Forensic and Investigative Accounting article A Forensic Accountant’s Guide to the Most Potent Federal Laws Used Against Healthcare Fraud asks whether a false statement got the government to pay. Applied here, that connects the laboratory representation to the company’s reimbursement claim. Engineering records explain the alleged falsehood. The purchasing, clinical and billing records connect it to what the government paid for.
For an insider, those records may sit in the company’s engineering, regulatory and reimbursement departments. We connect the manufacturer’s account of the processor to its requests for payment.
Advanced Bionics entered a five-year Corporate Integrity Agreement with the Department of Health and Human Services Office of Inspector General. The agreement required independent review of activities and processes used to prepare or submit premarket approval applications, along with the performance standards relevant to those applications.
The settlement announcement describes the required controls, including a risk assessment program and compliance certifications from key managers and the board of directors. Those requirements reached the path by which technical work became a representation to the FDA.
For a case about falsified processor testing, we connect what the laboratory actually tested, what the manufacturer told the FDA, what decision-makers knew and how the product reached a government-paid claim. The Advanced Bionics complaint shows why the details behind the result can be more useful than the word pass on the report.
An engineer may know which settings changed. A regulatory employee may know which results reached the FDA. The company’s own reimbursement staff may understand its requests for payment. A provider’s clinical or billing staff may understand the purchase and claim. We work with you to connect that technical knowledge to the health care payments and the decisions behind them.
The former Advanced Bionics engineer was allocated approximately $1.87 million from the federal settlement.
A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers. In this case, the insider’s contribution was his account of the testing itself: how the units were selected, how they were configured and what management did with the results. That is the kind of technical knowledge we help turn into a medical-device whistleblower case.
If you saw processor testing altered to produce a result the product could not reproduce in normal use, talk with our whistleblower experts about what happened inside the laboratory. We build the case with you and bring in medical-device whistleblower lawyers who understand engineering evidence, FDA submissions and government reimbursement. We stay beside you as the technical account becomes a case for recovering the government’s money.